Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Luca Gianni, Chiun‐Sheng Huang, Daniel Egle, Begoña Bermejo, C. Zamagni, Marc Thill, A. Antón, Stefania Zambelli, Giampaolo Bianchini, Salvatore Russo, Eva Ciruelos, Richard Greil, Semiglazov Vf, Marco Colleoni, Catherine M. Kelly, Gabriella Mariani, Lucia Del Mastro, I. Maffeis, Pinuccia Valagussa, Giuseppe Viale